Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanna Ko

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Gastroenterology and Hepatology|September 7, 2018
Inflammatory bowel disease environmental risk factors versus genetics based on migration epidemiological studiesYanna Ko
Medicine|September 8, 2023
Capsule endoscopy retention in the upper esophagus: A comprehensive literature reviewArteen Arzivian, Elke Wiseman, Yanna Ko
World Journal of Gastroenterology|February 28, 2014
Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseasesYanna Ko, Rhys Butcher, Rupert W Leong
Digestive Diseases (Basel, Switzerland)|March 17, 2016
Hygiene Hypothesis: Is the Evidence the Same All Over the World?Rupert W Leong, Nikola Mitrev, Yanna Ko
Therapeutic Advances in Gastroenterology|March 14, 2022
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyAviv Pudipeddi, Yanna Ko, Sudarshan Paramsothy, et al.
Alimentary Pharmacology & Therapeutics|June 21, 2021
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyYanna Ko, Sudarshan Paramsothy, Yunki Yau, et al.
Medicina (Kaunas, Lithuania)|November 27, 2024
A Review of Fecal Microbiota Transplantation in Children-Exploring Its Role in the Treatment of Inflammatory Bowel DiseasesYanna Ko, Sara Alaedin, Dewni Fernando, et al.
The Medical Journal of Australia|May 23, 2022
Ulcerative colitis and acute perimyocarditisKenneth K Cho, Yanna Ko, Kelly Nilsen, et al.
BMJ Open|October 3, 2023
Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocolTsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2024
Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' replyTsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Gastroenterology and Hepatology|September 7, 2018
Inflammatory bowel disease environmental risk factors versus genetics based on migration epidemiological studiesYanna Ko
Medicine|September 8, 2023
Capsule endoscopy retention in the upper esophagus: A comprehensive literature reviewArteen Arzivian, Elke Wiseman, Yanna Ko
World Journal of Gastroenterology|February 28, 2014
Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseasesYanna Ko, Rhys Butcher, Rupert W Leong
Digestive Diseases (Basel, Switzerland)|March 17, 2016
Hygiene Hypothesis: Is the Evidence the Same All Over the World?Rupert W Leong, Nikola Mitrev, Yanna Ko
Therapeutic Advances in Gastroenterology|March 14, 2022
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyAviv Pudipeddi, Yanna Ko, Sudarshan Paramsothy, et al.
Alimentary Pharmacology & Therapeutics|June 21, 2021
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyYanna Ko, Sudarshan Paramsothy, Yunki Yau, et al.
Medicina (Kaunas, Lithuania)|November 27, 2024
A Review of Fecal Microbiota Transplantation in Children-Exploring Its Role in the Treatment of Inflammatory Bowel DiseasesYanna Ko, Sara Alaedin, Dewni Fernando, et al.
The Medical Journal of Australia|May 23, 2022
Ulcerative colitis and acute perimyocarditisKenneth K Cho, Yanna Ko, Kelly Nilsen, et al.
BMJ Open|October 3, 2023
Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocolTsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2024
Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' replyTsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, et al.
Pageof 2